PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Low expression of nm23-H1 associates with poor survival of nasopharyngeal carcinoma patients: A prisma-compliant meta-analysis.

Abstract Developing a new reliable prognostic marker to predict the prognosis and supply better and more suitable therapy for patients with nasopharyngeal carcinoma (NPC) is urgent. Therefore, we performed this systematic review of the literature with meta-analysis to clarify and explore the associate expression of nm23-H1 with prognosis of NPC patients.
PMID
Related Publications

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma.

The expression of nm23-H1 and p53 protein in nasopharyngeal carcinoma.

Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma.

nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome.

Identification of nm23-H1 as a metastatic suppressor and prognostic factor in nasopharyngeal carcinoma by proteomic analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28614246
OWN - NLM
STAT- MEDLINE
DA  - 20170614
DCOM- 20170706
LR  - 20170706
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 24
DP  - 2017 Jun
TI  - Low expression of nm23-H1 associates with poor survival of nasopharyngeal
      carcinoma patients: A prisma-compliant meta-analysis.
PG  - e7153
LID - 10.1097/MD.0000000000007153 [doi]
AB  - BACKGROUND: Developing a new reliable prognostic marker to predict the prognosis 
      and supply better and more suitable therapy for patients with nasopharyngeal
      carcinoma (NPC) is urgent. Therefore, we performed this systematic review of the 
      literature with meta-analysis to clarify and explore the associate expression of 
      nm23-H1 with prognosis of NPC patients. METHODS: Literature research in Cochrane 
      Library, PubMed, and EMBASE was performed up to July 2016. Eligible case-control 
      studies of associate expression of nm23-H1 with prognosis of NPC patients were
      included. RESULTS: Nine studies met our inclusion criteria and were finally
      included for the analysis, involving 861 participants. Our meta-analysis revealed
      that the low expression of nm23-H1 in NPC was: RR = 2.13, 95% CI 1.15-3.95 and R 
      = 2.56, 95% CI 2.03-3.22; and poorer overall survival (OS) rate was 3-year OS
      rate: RR: 0.55; 95% CI: 0.45-0.67 and 5-year OS rate: RR: 0.60; 95% CI:
      0.52-0.69. Furthermore, the statistical significance was constant irrespective of
      different NPC subtypes. CONCLUSION: The low expression of nm23-H1 is associated
      with poorer prognosis in patients with NPC, suggesting that it is a prognostic
      factor and potential biomarker for survival in NPC.
FAU - Yuan, Cheng
AU  - Yuan C
AD  - aThe First College of Clinical Medical Science, China Three Gorges University
      bDepartment of Oncology, Yichang Central People's Hospital, Yichang cDepartment
      of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor
      Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan, China dZhongda 
      Hospital, Southeast University, Nanjing eCentral Hospital of Enshi Autonomous
      Prefecture, Enshi, China fKlinikum rechts der Isar Technical University of
      Munich, Munchen, Germany gBiomedical Engineering, Stony Brook University, Stony
      Brook, NY, USA.
FAU - Xu, Xin-Hua
AU  - Xu XH
FAU - Xu, Lu
AU  - Xu L
FAU - Sun, Min
AU  - Sun M
FAU - Ni, Li-Hua
AU  - Ni LH
FAU - Liu, Yang
AU  - Liu Y
FAU - Ran, Feng
AU  - Ran F
FAU - Wang, Xiao-Long
AU  - Wang XL
FAU - Chen, Zhuo
AU  - Chen Z
FAU - Zhang, Kun
AU  - Zhang K
FAU - Zeng, Guang
AU  - Zeng G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (NM23 Nucleoside Diphosphate Kinases)
RN  - EC 2.7.4.6 (NME1 protein, human)
RN  - Nasopharyngeal carcinoma
SB  - AIM
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma/diagnosis/*enzymology/*mortality
MH  - Humans
MH  - NM23 Nucleoside Diphosphate Kinases/*metabolism
MH  - Nasopharyngeal Neoplasms/diagnosis/*enzymology/*mortality
PMC - PMC5478331
EDAT- 2017/06/15 06:00
MHDA- 2017/07/07 06:00
CRDT- 2017/06/15 06:00
AID - 10.1097/MD.0000000000007153 [doi]
AID - 00005792-201706160-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jun;96(24):e7153. doi: 10.1097/MD.0000000000007153.